Vaayath Consulting Services
Regulatory Update · CDSCO / Gazette Notification

Drugs (Eighth Amendment) Rules, 2026: CLAA Licensing Framework Now Explicitly Covers Cell & Stem Cell Products, Gene Therapeutics and Xenografts

G.S.R. 530(E) brings advanced therapy products formally within the same Central Licence Approving Authority (CLAA) rules that have long governed r-DNA derived biologics — closing a long-standing regulatory ambiguity for India’s cell and gene therapy sector.

Notification: G.S.R. 530(E)
Dated: 29 June 2026
Published: 30 June 2026, Gazette No. 477
Issuing Authority: MoHFW, Dept. of Health & Family Welfare

The Central Government has notified the Drugs (Eighth Amendment) Rules, 2026, amending the Drugs Rules, 1945 to bring "Cell or Stem Cell derived products, Gene therapeutic products or Xenografts" explicitly within the licensing rules and application forms that were, until now, worded only around "Recombinant DNA (r-DNA) derived drugs."

What Has Actually Changed

Rules 75, 75A, 76 and 76A of the Drugs Rules, 1945 — the provisions governing licensing by the Central Licence Approving Authority (CLAA) for manufacture, sale, distribution and import of biotechnology-derived drugs — previously referred only to "Recombinant DNA (r-DNA) derived drugs." The Eighth Amendment inserts or substitutes this phrase throughout these rules and their associated Schedule A forms, so that it now reads as a combined category covering r-DNA derived drugs together with cell/stem cell derived products, gene therapeutic products and xenografts.

In practical terms: manufacturers, importers and sponsors of cell-based therapies, stem cell products, gene therapy products and xenograft-based products now fall squarely within CDSCO’s central licensing pathway for biotechnology products — the same pathway that r-DNA biologics have followed — rather than relying on inference or case-by-case CDSCO guidance.

Rule-by-Rule Summary

Regulatory Background

• 16 October 2025
  Draft rules published via G.S.R. 758(E) under Section 12(1) and Section 33(1) of the Drugs and Cosmetics Act, 1940, inviting public objections and suggestions.
• 18 October 2025
  Gazette copies made available to the public, starting the statutory 30-day objection window.
• Post objection window
  No objections or suggestions were received from stakeholders on the draft rules.
• 29 June 2026
  Central Government finalised the amendment after consultation with the Drugs Technical Advisory Board (DTAB), notifying the Drugs (Eighth Amendment) Rules, 2026.
• 30 June 2026
  Notification published in the Gazette of India (Extraordinary, Part II, Section 3(i), No. 477) and came into force on the date of publication.

Why This Matters for the Sector

Cell & Stem Cell Therapy Companies

Manufacture and import activities are now unambiguously routed through CLAA under Rules 75–76A, rather than being assessed against provisions drafted only with r-DNA drugs in mind.

Gene Therapy Developers

Gene therapeutic products gain a defined statutory home within the central licensing scheme, supporting more predictable timelines for manufacturing and import approvals.

Xenograft Product Manufacturers

Xenografts are named for the first time in these rules, addressing a category that had limited explicit coverage under the pre-amendment framework.

MAHs & Regulatory Affairs Teams

Existing and pending applications on Forms 27D/27DA (manufacturing) and 28D/28DA (import) should be reviewed against the amended headings and inserted text before the next filing cycle.

Compliance Checklist

• Confirm whether your product falls under "Cell or Stem Cell derived products," "Gene therapeutic products," or "Xenografts" as newly referenced in Rules 75, 75A, 76 and 76A.
• Route new manufacturing licence applications for these product categories through CLAA using the amended Form 27D / 27DA.
• Route new import licence applications through CLAA using the amended Form 28D / 28DA.
• Review any pending applications filed before 30 June 2026 to check if resubmission or clarification is warranted under the updated headings.
• Update internal SOPs, regulatory dossiers and labelling references that currently cite only "r-DNA derived drugs" as the licensing category.
• Track related amendments — this Eighth Amendment follows closely on the Seventh Amendment (G.S.R. 506(E), 22 June 2026), so maintain a consolidated view of the current Drugs Rules, 1945 text.

Legal & Document References

Primary Notification: G.S.R. 530(E), dated 29 June 2026, Ministry of Health and Family Welfare (Department of Health and Family Welfare)

• Enabling provisions: Section 12(1) and Section 33(1), Drugs and Cosmetics Act, 1940 (23 of 1940)
• Draft notification: G.S.R. 758(E), dated 16 October 2025
• Consultative body: Drugs Technical Advisory Board (DTAB)
• Parent rules: Drugs Rules, 1945 (notified vide F. 28-10/45H(1), dated 21 December 1945)
• Immediately preceding amendment: G.S.R. 506(E), dated 22 June 2026 (Seventh Amendment)
• Gazette reference: Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), No. 477, dated 30 June 2026

Need Help Assessing Impact on Your Licensing Filings?

Vaayath Consulting Services can help map your cell, gene therapy or xenograft product portfolio against the amended CLAA rules and prepare compliant Form 27D/27DA and 28D/28DA submissions.

Write to info@vaayath.com
Vaayath Consulting Services Private Limited — Regulatory Advisory for Pharmaceuticals & Healthcare
This article is for general informational purposes and does not constitute legal advice. For guidance specific to your product or licence, please contact our regulatory team at info@vaayath.com.